Bausch Health Companies Inc. (BHC) Stock Analysis
Healthcare · Drug Manufacturers - Specialty & Generic · NYSE
Bausch Health Companies Inc. (BHC) posted $10.27B in revenue for fiscal 2025 (up 6.7% year over year), at a 1.5% net margin, and has compounded revenue about 5.0%/yr over five years, per its SEC filings.
Data last refreshed August 2, 2026 from SEC filings · how we compute this
The analyst's take on Bausch Health Companies Inc.
Bausch Health Companies Inc. has grown revenue from $9.67B to $10.27B over the last 10 fiscal years, compounding about 5% a year. The most recent year was up 6.7%, so growth is actually accelerating.
Net margin sits at 1.5%, up 2 points year over year on a 70.7% gross margin. It carries about $20.82B of total debt.
At today's valuation the market is pricing in roughly -29.1% annual free-cash-flow growth — versus the 4.2% it actually delivered over the last five years, so the price is arguably undemanding against what it has already proven. The one thing worth a second look in the filings is heavy debt load.
Synthesised from Bausch Health Companies Inc.'s SEC filings — descriptive, not advice. Ask the analyst your own question →
Bausch Health Companies Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.67B | $8.72B | $8.38B | $8.60B | $8.03B | $8.43B | $8.12B | $8.76B | $9.63B | $10.27B |
| Gross profit | $7.10B | $6.22B | — | — | — | — | $5.76B | $6.20B | $6.84B | $7.25B |
| Net income | $-2.41B | $2.40B | $-4.14B | $-1.79B | $-560.00M | $-948.00M | $-225.00M | $-592.00M | $-46.00M | $157.00M |
| Net margin | -24.9% | 27.6% | -49.5% | -20.8% | -7.0% | -11.2% | -2.8% | -6.8% | -0.5% | 1.5% |
Source: Bausch Health Companies Inc. SEC filings (10-K). 18 years of history available in the interactive view.
Bausch Health Companies Inc.: 1 potential red flag in the filings
Patterns in the filed statements worth a second look — computed and cited, not AI guesswork, and not a signal to sell. The kind of thing that hides in a 10-K.
- Heavy debt loadTotal debt of $21042M is 15.0× last year's operating cash flow — it would take years of cash flow to clear.
What growth is priced into BHC stock?
At today's market cap of $1.95B, Bausch Health Companies Inc. is priced for free-cash-flow growth of about -29.1% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $993.00M from the FY ending 2025-12-31). For comparison, free cash flow actually grew 4.2%/yr over the last five fiscal years and revenue 5%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 18 years of Bausch Health Companies Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track BHC in your portfolio →
Bausch Health Companies Inc. financial history by metric
About Bausch Health Companies Inc.
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health. The company sells its products in the United States, China, Canada, Poland, Mexico, France, South Korea, Russia, Japan, Germany, the United Kingdom, Spain, Italy, and internationally. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
Bausch Health Companies Inc. — frequently asked questions
What is Bausch Health Companies Inc.'s revenue?
Bausch Health Companies Inc. (BHC) reported revenue of $10.27B for fiscal year 2025, up 6.7% from the prior year, according to its SEC filings.
Is Bausch Health Companies Inc. profitable?
Yes. BHC earned net income of $157.00M in fiscal 2025, a net margin of 1.5%.
What is BHC's P/E ratio?
Bausch Health Companies Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Bausch Health Companies Inc. growing?
BHC's revenue grew at roughly 5.0% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Bausch Health Companies Inc. have?
As of fiscal year 2025, BHC carried roughly $20.82B in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Bausch Health Companies Inc.'s gross margin?
BHC's gross margin was 70.7% in fiscal 2025 — gross profit of $7.25B on revenue of $10.27B.
What is Bausch Health Companies Inc.'s market cap?
Bausch Health Companies Inc. (BHC) has a market capitalization of about $1.95B, based on the latest data in our nightly-refreshed cache.
When does Bausch Health Companies Inc.'s fiscal year end?
BHC's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into BHC stock?
At today's market cap of $1.95B, Bausch Health Companies Inc. is priced for free-cash-flow growth of about -29.1% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $993.00M from the FY ending 2025-12-31). For comparison, free cash flow actually grew 4.2%/yr over the last five fiscal years and revenue 5%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from Bausch Health Companies Inc.'s official SEC filings (10-K and 10-Q), covering 18 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.